Posted on 28.09.2016
Ziarco Pharma is a biotechnology company, progressing patient trials for a range of new therapies for inflammatory and allergic diseases. Discovery Park has been at the heart of its success.
The company has been part of the Discovery Park community since April 2015, with its team growing four to 12, with five staff added since re-locating from its previous Canterbury base.
Ziarco Pharma is focused on developing drugs for the treatment of inflammatory and dermatological diseases such as atopic dermatitis and psoriasis.
In August, the company was announced as a finalist in the OBN Awards 2016 in the best Emerging Biotech company category. This recognition came weeks after reporting positive Phase2a study results with ZPL-389 in moderate to severe atopic dermatitis patients.
CEO Mike Yeadon was formerly the Vice President and Chief Scientific Officer for Pfizer’s Allergy & Respiratory Research Unit at Sandwich, where he helped with the discovery and development of oral and inhaled new chemical entities (NCEs) for a range of respiratory diseases.
Chief Development Officer, Dr Lynn Purkins believes Discovery Park offers the best environment for the company’s needs. She said:
“We have been impressed by the development of the park since 2012 and the number of successful businesses that have joined the site.
“Discovery Park offers us room to grow and a lot of our neighbouring companies have skills and facilities we can work with to further establish the business.”
“We recognised there were a number of potential life sciences and supporting facilities companies which Ziarco could work with in addition to our existing commercial relationships.”
To find out about the work of Ziarco, visit: www.ziarcopharma.com